Company intelligence / Profile preview
Edity Therapeutics
Rehovot, HaMerkaz, Israeledity-tx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Edity Therapeutics has demonstrated proof-of-concept for its platform in preclinical studies. The company’s technology enables immune cells to deliver functional therapeutic proteins directly into the cytoplasm of target diseased cells—a capability that addresses limitations of current modalities regarding tissue targeting and payload size. No clinical results have been published as of May 2025
- Therapeutic areas
- Oncology
- Modalities
- Immune cell-based therapiesengineered immune cells delivering therapeutic proteins (intracellular protein delivery)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Strategic co-development partnership announced April 2025; partner name not disclosed as of latest update
Beyond the preview
Go deeper on Edity Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Edity Therapeutics.